Simian Daniela, Quijada María Isabel, Lubascher Jaime, Acuña Raúl, Quera Rodrigo
Rev Med Chil. 2013 Sep;141(9):1158-65. doi: 10.4067/S0034-98872013000900008.
Biological therapy has an important role in the treatment of Inflammatory Bowel Disease (IBD). However, the use of these drugs is resisted due to fears about their side effects.
To report the experience with the use of Infliximab in patients with IBD.
Descriptive study of a historical cohort of patients with IBD treated between 2007 and 2012 with Infliximab. A favorable clinical response was considered when general, intestinal and extra-intestinal symptoms subsided after the second or third dose of the drug. Endoscopic or imaging response was evaluated between three and six months of treatment.
Twenty five patients aged 18 to 61 years (12 women) were included. Sixteen had Cohn's Disease and 9 had Ulcerative Colitis. Treatment was indicated due to refractory disease in 13 patients, perianal involvement in nine, stenosis in two and pyoderma gangrenosum in one. Ten patients initiated Infliximab within less than two years of diagnosis. Twenty-two patients received combined treatment with immunosuppressive medications and the other three patients were treated exclusively with Infliximab. A favorable clinical response was observed in 88% after the second dose and 64% had endoscopic or imaging remission after 3-6 months. Twelve patients discontinued Infliximab, due to bad response to treatment in three patients, economic cost in three patients, and patient/doctor decision in six. Only three patients had side effects (herpes zoster and sinusitis). None of these motivated the discontinuation of treatment.
In this cohort of patients with IBD, the use of Infliximab was associated with endoscopic or imaging remission in 64% of cases after 3-6 months of treatment with no major side effects.
生物疗法在炎症性肠病（IBD）的治疗中具有重要作用。然而，由于担心其副作用，这些药物的使用受到抵制。
报告英夫利昔单抗在IBD患者中的使用经验。
对2007年至2012年间接受英夫利昔单抗治疗的IBD患者历史队列进行描述性研究。当在第二或第三剂药物后全身、肠道和肠外症状消退时，认为临床反应良好。在治疗三至六个月之间评估内镜或影像学反应。
纳入了25例年龄在18至61岁之间的患者（12名女性）。16例患有克罗恩病，9例患有溃疡性结肠炎。13例患者因难治性疾病、9例因肛周受累、2例因狭窄、1例因坏疽性脓皮病而接受治疗。10例患者在诊断后不到两年内开始使用英夫利昔单抗。22例患者接受了免疫抑制药物联合治疗，另外3例患者仅接受英夫利昔单抗治疗。第二剂后88%的患者观察到良好的临床反应，3至6个月后64%的患者内镜或影像学缓解。12例患者停用英夫利昔单抗，3例患者因治疗反应不佳、3例患者因经济成本、6例患者因患者/医生决定。只有3例患者有副作用（带状疱疹和鼻窦炎）。这些均未导致治疗中断。
在这个IBD患者队列中，使用英夫利昔单抗治疗3至6个月后，64%的病例出现内镜或影像学缓解，且无重大副作用。
